Comparative Pharmacology
Head-to-head clinical analysis: FLUOTHANE versus KETAMINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUOTHANE versus KETAMINE HYDROCHLORIDE.
FLUOTHANE vs KETAMINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Halothane enhances GABA-A receptor activity and inhibits NMDA receptors, leading to neuronal hyperpolarization and decreased excitability. It also potentiates glycine receptor function and disrupts synaptic transmission via interaction with voltage-gated sodium channels.
Noncompetitive NMDA receptor antagonist; also interacts with opioid receptors, monoaminergic receptors, and voltage-gated calcium channels.
Induction: 0.5-3% halothane in oxygen or nitrous oxide/oxygen; maintenance: 0.5-1.5%.
Induction: 1-2 mg/kg IV, 0.5-1 mg/kg/min IV infusion for maintenance. Dissociative sedation: 1-1.5 mg/kg IV or 3-4 mg/kg IM. Pain management: 0.1-0.5 mg/kg IV bolus followed by 0.1-0.4 mg/kg/h IV infusion.
None Documented
None Documented
Terminal elimination half-life is biphasic: initial 2-5 minutes (rapid redistribution), terminal 15-20 hours for trace amounts in adipose tissue due to slow release; contextually, emergence from anesthesia occurs within minutes.
Terminal elimination half-life of ketamine is 2.5–3 hours; norketamine half-life is approximately 4 hours. Context: Prolonged elimination may occur with hepatic impairment or high-dose infusions.
Primarily exhaled unchanged via the lungs; negligible renal (0.5% as metabolites) and fecal elimination.
Ketamine is primarily metabolized in the liver via N-demethylation to norketamine. Renal excretion accounts for approximately 90% of the dose, with 4% as unchanged drug, 16% as norketamine, and the remainder as conjugated metabolites. Fecal excretion is minimal (<5%).
Category C
Category C
General Anesthetic
General Anesthetic